In 2000, Tazebay et al. discovered that most (approximately 80%) breast carcinomas have pronounced cytoplasmic NIS expression, which initiated many studies in this area, the interim result of which can be considered the work of Peyrottes et al., 2009, which presents arguments in favor of the non-specific nature of staining with NIS antibodies and a significantly lower actual level of expression of this protein [12,13]. Here, SLC5A5 is linked to breast carcinoma.